After layers of screening and evaluation, Tangneng Translation stood out among multiple medical translation service providers and formally signed a cooperation agreement with Shengen Biotech Co., Ltd. (688289) on June 15, 2021, becoming the winning translation supplier for Shengen Biotech's 2021-2022 annual translation service procurement project.
The scope of Shengen Biotech's tender includes multilingual written and oral translation services. In addition to Chinese-English translation, it involves more than 20 non-English languages, including the 24 official languages of the European Union.
About Shengen Biotech.
Shengen Biotech Co., Ltd. is an integrated in vitro diagnostic solution provider centered on self-innovative genetic technology, integrating diagnostic reagents, instruments, and third-party medical testing services. Listed on the Sci-Tech Innovation Board (stock code: 688289), it has been selected as a sample stock of the "STAR Market 50" index.
Shengen Biotech has dedicated itself to creating high-quality products, developing over 400 products in fields such as infectious disease prevention and control, cancer prevention and control, maternal and child health, blood screening, emergency epidemic prevention and control, and chronic disease management—with performance surpassing advanced domestic and international standards. It offers over 2,200 types of testing services, forming a full-industry-chain system solution integrating reagents, instruments, sequencing services, third-party medical testing services, and molecular laboratory construction. Its products are sold to more than 160 countries and regions worldwide.
Recently, in the highly anticipated "2020 China Pharmaceutical Industry Top 100 List," Sinopharm Group, Yangtze River Pharmaceutical, and Guangyao Group ranked top three. Shengen Biotech ranked 59th, becoming the first biomedical enterprise from Hunan Province to be listed. As a key force in the anti-epidemic effort, Shengen Biotech's COVID-19 nucleic acid testing products have served more than 160 countries and regions, accurately targeting variants such as Delta. The "Shengen Solution" has become the leading nucleic acid testing program for global anti-epidemic efforts in many countries.
Winning the translation project for Shengen Biotech once again highlights Tangneng Translation's growing corporate strength and trustworthy service quality. Tangneng has a large team of professional translators in the pharmaceutical and medical fields, covering 61 languages globally with English, Japanese, and German as core languages. It has maintained long-term and good cooperative relationships with major biomedical and medical device companies, such as Junshi Biosciences, Qilu Pharmaceutical, East China Pharmaceutical, Shanghai Bio-Kang, Shiyao Group, Shengen Biotech, BGI, Sami Medical, Yuanhe Medical, Santen, Prologue, Charles River, Berkeley Lights, Kyowa Hakko Kirin,Hope Medicine Inc.，Eppendorf AG, Advaccine, United Imaging Healthcare, and Sartorius, among others.
In the future, Tangneng Translation will continue to uphold craftsmanship, providing higher-quality oral and written translation services for clients across industries and advancing their globalization efforts.
